Extended prophylaxis with idraparinux prevented recurrence of venous thromboembolism but increased risk for bleeding

January 2008
ACP Journal Club;Jan/Feb2008, Vol. 148 Issue 1, p20
Academic Journal
The article presents a study which examines the effectiveness of idraparinux in treating patients with venous thromboembolism (VTE) who have completed six months of anticoagulant therapy. In patients with VTE who had completed six months of anticoagulant therapy, study shows that idraparinux reduced risk for recurrent VTE more than placebo in the following six months but increased risk for bleeding.


Related Articles

  • Vitamin K KO'd by Placebo for Overanticoagulation.  // Clinician Reviews;Apr2009, Vol. 19 Issue 4, p28 

    The article discusses research being done on vitamin K. It references a study by M. A. Crowther et al that was published in a 2009 issue of "Annals of Internal Medicine." The study found that in a head-to-head comparison with placebo, low-dose oral vitamin K did not effectively reduce bleeding...

  • Risk of Bleeding While Taking Oral Anticoagulants. Sadovsky, Richard // American Family Physician;8/15/2004, Vol. 70 Issue 4, p770 

    Discusses research being done on the clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism. Reference to a study by L.A. Linkins et al published in an issue of "Annals of Internal Medicine" journal; Factors being considered in deciding on the...

  • Low-dose warfarin prevents recurrent thromboembolism. Plum, Mary-Beth Fennell // Journal of Family Practice;Aug2003, Vol. 52 Issue 8, p588 

    The article discusses research on the use of low-dose warfarin to prevent recurrent venous thromboembolism. Low-dose warfarin does not increase the risk of major bleeding when used for secondary prophylaxis. This should follow after three to twelve months of full-intensity warfarin after the...

  • Aspirin in the primary prophylaxis of venous thromboembolism in surgical patients. Sahebally, Shaheel M.; Healy, Donagh; Walsh, Stewart R. // Surgeon (Elsevier Science);Dec2015, Vol. 13 Issue 6, p348 

    Introduction: Venous thromboembolism (VTE) is a common complication in surgical patients, especially those undergoing lower limb orthopaedic procedures as well as oncological resectional surgery. Numerous studies have evaluated the role of acetylsalicylic acid (ASA, aspirin) in...

  • Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis. Caldeira, Daniel; Rodrigues, Filipe B.; Barra, Márcio; Santos, Ana Teresa; de Abreu, Daisy; Gonçalves, Nilza; Pinto, Fausto J.; Ferreira, Joaquim J.; Costa, João // Heart;Aug2015, Vol. 101 Issue 15, p1204 

    Objective Non-vitamin K antagonist oral anticoagulants (NOACs) are efficacious and safe antithrombotic drugs but the non-availability of an antidote for potential fatal haemorrhagic events is clinically perceived as a strong limitation. We aimed at evaluating the risk of haemorrhage-related...

  • Venous Thrombosis as a Chronic Disease. Schafer, Andrew I. // New England Journal of Medicine;03/25/99, Vol. 340 Issue 12, p955 

    Editorial. Comments on treatment of thromboembolism with oral anticoagulants such as warfarin. Reference to the study by Kearon and associates in this issue; The cumulative risks of bleeding complications; Suggestion that venous thromboembolism is a chronic rather than acute disease.

  • Left Atrial Appendage Closure: Initial Experience with the Watchman Device. Toutouzas, Konstantinos; Trantalis, George; Benetos, Georgios; Sideris, Skevos; Aggeli, Konstantina; Stefanadis, Christodoulos // Hospital Chronicles;2014, Vol. 9 Issue 2, p1 

    We herein present the first left atrial appendage (LAA) percutaneous closure procedure performed in our Institution with use of the Watchman device in an 82-year old woman with atrial fibrillation, unable to continue receiving anticoagulation therapy due to bleeding complications. A propos with...

  • Coumarins: lowering target INR decreases complication risk.  // Reactions Weekly;5/29/2004, Issue 1003, p4 

    Discusses research being done on the effect of lowering the intensity of anticoagulant coumarins therapy on the risk of hemorrhage and thromboembolism. Reference to a study by M. Torn et al, published in the March 2004 issue of "Archives of Internal Medicine"; Decrease in incidence of bleeding...

  • Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism. Ridker, Paul M; Goldhaber, Samuel Z.; Danielson, Ellie; Rosenberg, Yves; Eby, Charles S.; Deitcher, Steven R.; Cushman, Mary; Moll, Stephan; Kessler, Craig M.; Elliott, C. Gregory; Paulson, Rolf; Wong, Turnly; Bauer, Kenneth A.; Schwartz, Bruce A.; Miletich, Joseph P.; Bounameaux, Henri; Glynn, Robert J. // New England Journal of Medicine;4/10/2003, Vol. 348 Issue 15, p1425 

    Background: Standard therapy to prevent recurrent venous thromboembolism includes 3 to 12 months of treatment with full-dose warfarin with a target international normalized ratio (INR) between 2.0 and 3.0. However, for long-term management, no therapeutic agent has shown an acceptable...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics